155 results on '"Castellino, Stephen"'
Search Results
2. Multimodal imaging distribution assessment of a liposomal antibiotic in an infectious disease model
3. Intramuscular and subcutaneous drug depot characterization of a long-acting cabotegravir nanoformulation by MALDI IMS
4. Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat
5. Assessing drug and metabolite detection in liver tissue by UV-MALDI and IR-MALDESI mass spectrometry imaging coupled to FT-ICR MS
6. Table S1 from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
7. Figures S1-S10 from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
8. Supplementary Materials from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
9. Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies
10. Imaging MS in Toxicology: An Investigation of Juvenile Rat Nephrotoxicity Associated with Dabrafenib Administration
11. Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity
12. A Multimodal Imaging Approach to Assess the Quantitative Biodistribution of a Liposomal Nanoformulation with the antibiotic GSK2485680 (Lipo680)
13. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
14. Mapping the Lipids of Skin Sebaceous Glands and Hair Follicles by High Spatial Resolution MALDI Imaging Mass Spectrometry
15. GlycoFibroTyper: A Novel Method for the Glycan Analysis of IgG and the Development of a Biomarker Signature of Liver Fibrosis
16. Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
17. The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions
18. MALDI imaging MS analysis of drug distribution in tissue: the right time!(?)
19. The emergence of imaging mass spectrometry in drug discovery and development: Making a difference by driving decision making
20. MALDI imaging mass spectrometry: bridging biology and chemistry in drug development
21. Guest editorial for special issue on imaging mass spectrometry
22. Special issue on imaging mass spectrometry
23. Quantification and assessment of detection capability in imaging mass spectrometry using a revised mimetic tissue model
24. Multicenter Validation Study of Quantitative Imaging Mass Spectrometry
25. Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
26. Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
27. An Investigation into Retigabine (Ezogabine) Associated Dyspigmentation in Rat Eyes by MALDI Imaging Mass Spectrometry
28. Revised Preparation of a Mimetic Tissue Model for Quantitative Imaging Mass Spectrometry
29. Visualizing drug disposition with MALDI imaging MS
30. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
31. Investigation of Blue Bedding in Cages Housing Treatment-Naïve Hamsters
32. HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2
33. Drug-induced Liver Fibrosis
34. MALDI Imaging MS: Molecular Visualization of Tissues in Drug Discovery and Development
35. Cardiolipin profiles as a potential biomarker of mitochondrial health in diet-induced obese mice subjected to exercise, diet-restriction and ephedrine treatment
36. High-resolution MALDI imaging MS in drug development
37. A Mimetic Tissue Model for the Quantification of Drug Distributions by MALDI Imaging Mass Spectrometry
38. Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans
39. Et2AlCl complexes of an N-acyloxazolidinone: NMR investigation
40. Central Nervous System Disposition and Metabolism of Fosdevirine (GSK2248761), a Non-Nucleoside Reverse Transcriptase Inhibitor: An LC-MS and Matrix-Assisted Laser Desorption/Ionization Imaging MS Investigation into Central Nervous System Toxicity
41. Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
42. Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity
43. The disposition and metabolism of GW695634: A non-nucleoside reverse transcriptase inhibitor (NNRTi) for treatment of HIV/AIDS
44. An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016): TABLE 1
45. The Role of Efflux and Uptake Transporters inN-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions
46. Allyltributylstannane
47. Tin(IV) Chloride
48. Allyltributylstannane
49. Tin(IV) Chloride-Zinc Chloride
50. Crotyltributylstannane
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.